Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD Has $21.36 Million Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Key Points

• Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD increased its stake in Cellebrite DI Ltd. by 8.2% in Q1, owning over 1,099,715 shares valued at approximately $21.36 million.
• Cellebrite DI reported $0.10 earnings per share (EPS) for the most recent quarter, beating consensus estimates and achieving a 20% year-over-year revenue increase to $107.55 million.
• With 45.88% of its shares held by institutional investors, the stock currently has an average rating of "Buy" and a target price of $22.43, according to analysts.

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD boosted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 8.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,099,715 shares of the company's stock after acquiring an additional 83,687 shares during the quarter. Cellebrite DI comprises about 1.7% of Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD's holdings, making the stock its 18th largest holding. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD owned approximately 0.46% of Cellebrite DI worth $21,356,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. FMR LLC increased its holdings in Cellebrite DI by 89.1% in the fourth quarter. FMR LLC now owns 10,621,344 shares of the company's stock valued at $233,988,000 after buying an additional 5,004,587 shares during the last quarter. Axon Enterprise Inc. bought a new position in Cellebrite DI during the 4th quarter worth $198,270,000. Voss Capital LP boosted its holdings in shares of Cellebrite DI by 1.2% during the fourth quarter. Voss Capital LP now owns 3,240,000 shares of the company's stock valued at $71,377,000 after acquiring an additional 39,700 shares during the period. Pertento Partners LLP lifted its position in Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock valued at $65,547,000 after purchasing an additional 626,373 shares during the last quarter. Finally, Crescent Park Management L.P. raised its holdings in shares of Cellebrite DI by 8.3% during the fourth quarter. Crescent Park Management L.P. now owns 1,862,482 shares of the company's stock valued at $41,030,000 after buying an additional 142,534 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Stock Down 0.8%

NASDAQ:CLBT traded down $0.12 during trading hours on Wednesday, reaching $14.37. 378,832 shares of the company's stock were exchanged, compared to its average volume of 1,567,376. The company has a market capitalization of $3.44 billion, a P/E ratio of -14.94, a price-to-earnings-growth ratio of 2.90 and a beta of 1.28. Cellebrite DI Ltd. has a 12 month low of $11.90 and a 12 month high of $26.30. The business's 50-day simple moving average is $15.69 and its two-hundred day simple moving average is $18.60.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million during the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The company's revenue was up 20.0% compared to the same quarter last year. During the same period last year, the company posted $0.08 EPS. As a group, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on CLBT shares. Needham & Company LLC reissued a "buy" rating and issued a $24.00 price target on shares of Cellebrite DI in a research note on Friday, June 6th. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI has a consensus rating of "Buy" and a consensus price target of $22.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.